Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Summary

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to prevent angioedema attacks in participants aged ≥ 12 years with hereditary angioedema.

Timeline

Start

2024-12-01

Primary completion

2026-08

Completion

2026-08

Outcome

Met primary endpoint

release “today announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablet” pharvaris.com ↗

release “The primary endpoint and all secondary efficacy endpoints were met with statistical significance.” pharvaris.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRICTIBANT	Small molecule	40 mg	Oral

Indications